Shares of Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) have received a consensus rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $37.83.
OMCL has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Benchmark reiterated a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research report on Monday, July 15th. Bank of America increased their price objective on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Wells Fargo & Company boosted their target price on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday.
Read Our Latest Analysis on OMCL
Hedge Funds Weigh In On Omnicell
Omnicell Price Performance
Shares of OMCL stock opened at $43.42 on Friday. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.58. The company has a market capitalization of $2.00 billion, a P/E ratio of -94.39, a P/E/G ratio of 47.22 and a beta of 0.83. The stock has a 50 day moving average of $38.85 and a two-hundred day moving average of $32.12. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47.
Omnicell (NASDAQ:OMCL – Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS. As a group, equities analysts expect that Omnicell will post 0.64 EPS for the current year.
About Omnicell
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Read More
- Five stocks we like better than Omnicell
- How to Most Effectively Use the MarketBeat Earnings Screener
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- How to Use Stock Screeners to Find Stocks
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- The Risks of Owning Bonds
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.